<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">The highest rate of mild to moderate influenza disease (MMID) was observed in the placebo group, with 54.8% of participants experiencing MMID. In the two-dose FLU-v group, 36.6% (
 <italic>p</italic> = 0.075) experienced MMID while 32.5% (
 <italic>p</italic> = 0.035) experienced MMID in the one-dose FLU-v group, a statistically significant reduction in the primary endpoint vs the placebo group (Table 
 <xref rid="Tab2" ref-type="table">2</xref>).
</p>
